Home › CHMP Issues Positive Opinion for Intravenous (IV) Formulation of Mercks NOXAFIL (posaconazole)
 

Keywords :   


CHMP Issues Positive Opinion for Intravenous (IV) Formulation of Mercks NOXAFIL (posaconazole)

2014-07-30 14:00:03| Merck.com - Research & Development News

Dateline City: WHITEHOUSE STATION, N.J. WHITEHOUSE STATION, N.J., July 30, 2014 Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending approval of a new, investigational intravenous (IV) formulation of NOXAFIL (posaconazole). Language: English read more

Tags: issues positive opinion formulation

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
03.07High input costs, rising interest rates continue to weigh on farmer sentiment
03.07Sensory analysis shows pork has 111 unique flavor nuances
03.07Hurricane Beryl Graphics
03.07Hurricane Beryl Public Advisory Number 19A
03.07Summary for Hurricane Beryl (AT2/AL022024)
03.07'Floodgates open' for legal action against water firms
03.07Atlantic Tropical Weather Outlook
03.07Eastern North Pacific Tropical Weather Outlook
More »